C4221026: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509408-13-00

Acronym

C4221026

Enrollment

Registered

2024-08-27

Start date

2022-09-20

Completion date

Unknown

Last updated

2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Brief summary

AEs leading to permanent discontinuation of study interventiona, All SAEs

Interventions

DRUGBraftovi 75 mg hard capsules

DRUGRibociclib

DRUGZelboraf 240 mg film-coated tablets

DRUGMektovi 15 mg film-coated tablets

DRUGErbitux 5 mg/mL solution for infusion

DRUGEncorafenib

DRUGNIVOLUMAB

DRUGPEMBROLIZUMAB

DRUGBraftovi 50 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
AEs leading to permanent discontinuation of study interventiona, All SAEs	—

Countries

Czechia, France, Germany, Hungary, Italy, Netherlands, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026